2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 15: November 13, 2024 - What Did 2024 Bring to the Table in Dermatology? Best of FC24 Clinical Review
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, November 13, 2024
8 PM ET / 5 PM PT
What Did 2024 Bring to the Table in Dermatology? The Best of FC24 Clinical Review
Part 1: Atopic Dermatitis, GPP, Psoriasis, Chronic Inflammatory Diseases, and More
Part 2: Acne, Contact Dermatitis, Pediatric Dermatology, Skin Cancer, and More
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 14, 2024
November 14, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the pathogenesis and optimal management of psoriasis, atopic dermatitis and acne vulgaris
Update knowledge regarding recent advances in the safe and effective use of biologic agents for the treatment of dermatologic diseases
Enhance the ability to evaluate and incorporate new techniques and uses of dermal fillers and neurotoxins
Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents approved for use in the dermatology setting Integrate prevention, diagnosis, and management of skin cancer into my clinical setting
Diagnose commonly presented dermatologic disorders
Improve my clinical interactions with patients
Integrate knowledge to enhance daily dermatologic care
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Boni Elewski, MD
James Elder Professor and Chair of Dermatology
University of Alabama at Birmingham
Birmingham, AL
Dirk Elston, MD
Chairman, Department of Dermatology
Medical University of South Carolina
Charleston, SC
Laura Ferris, MD, PhD
Professor and Director of Clinical Trials, Dermatology
University of Pittsburgh
Pittsburgh, PA
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Emmy Graber, MD
President, The Dermatology Institute of Boston
Affiliate Clinical Instructor
Northeastern University
Boston, MA
Theodore Rosen, MD
Professor of Dermatology
Baylor College of Medicine
Chief of the VA Dermatology Service
VA Medical Center
Houston, TX
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
Grant/Research Support: Ortho Dermatology
Consultant: Ortho Dermatology
No relevant financial relationships with any Ineligible Company in the past 24 months.
Advisory Board: DermTech, Boerhinger-Ingelheim, AbbVie, Bristol-Myers Squibb, Arcutis, Dermavant, Cara Therapeutics, Leo Pharma, Regeneron, Amgen, Janssen, Novartis Grant/Research Support: AbbVie, Bristol-Myers Squibb, DermTech, Castle Biosciences, Arcutis, Amgen, Janssen, Eli Lilly, Novartis, UCB, Moberg, Aristea, Acelyrin, Cara Therapeutics, Leo Pharma, Regeneron, SkinAnalytics Consultant: DermTech, Boerhinger-Ingelheim, AbbVie, Bristol-Myers Squibb, Arcutis, Dermavant, Cara Therapeutics, Leo Pharma, Pfizer, Regeneron, Amgen, Janssen, Novartis, Sanofi Speakers’ Bureau or Honoraria: Boerhinger-Ingelheim, Bristol-Myers Squibb, Arcutis, Regeneron, Abbvie
Advisory Board: Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi
Consultant: Abbvie, Arcutis, Dermavant, Galderma, Lilly, Regeneron, Sanofi
Speakers’ Bureau Honoraria: Abbvie, Arcutis, Dermavant, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi
Grant/Research Support: Hovione, Ortho Dermatologics, Sebacia
Consultant: Digital Diagnostics, Almirall, Cutera, Hovione, La Roche Posay, Lipidor AB, Ortho Dermatologics, Sebacia, Sol Gel, Verrica, WebMD
Speakers’ Bureau or Honoraria: L’Oreal, Almirall, Cutera
Royalty: Wolters Kluwer Health
Ownership Interest: Digital Diagnostics, Cutera
Advisory Board: Verrica Pharmaceuticals
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.